Role of inactivated SARS-CoV-2 vaccine induced T cell responses in ameliorating COVID-19 severity

Huang, Hongming; Liu, Jia

doi:10.1016/j.virs.2023.02.003

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This hinders optimal engagement with the host’s immune repertoire. Furthermore, these approaches are poor inducers of cytotoxic CD8+ T cells, which are crucial for an effective COVID-19 vaccine [ 13 , 14 , 15 ]. Subunit vaccines also lack the repetitive antigenic structure on their surface, which is essential for efficient recognition by immune cells.…”

Section: Introductionmentioning

confidence: 99%

Rapid and Scalable Production of Functional SARS-CoV-2 Virus-like Particles (VLPs) by a Stable HEK293 Cell Pool

Puarattana-aroonkorn,

Tharakaraman,

Suriyawipada

et al. 2024

Vaccines

View full text Add to dashboard Cite

At times of pandemics, such as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the situation demands rapid development and production timelines of safe and effective vaccines for delivering life-saving medications quickly to patients. Typical biologics production relies on using the lengthy and arduous approach of stable single-cell clones. Here, we used an alternative approach, a stable cell pool that takes only weeks to generate compared to a stable single-cell clone that needs several months to complete. We employed the membrane, envelope, and highly immunogenic spike proteins of SARS-CoV-2 to produce virus-like particles (VLPs) using the HEK293-F cell line as a host system with an economical transfection reagent. The cell pool showed the stability of protein expression for more than one month. We demonstrated that the production of SARS-CoV-2 VLPs using this cell pool was scalable up to a stirred-tank 2 L bioreactor in fed-batch mode. The purified VLPs were properly assembled, and their size was consistent with the authentic virus. Our particles were functional as they specifically entered the cell that naturally expresses ACE-2. Notably, this work reports a practical and cost-effective manufacturing platform for scalable SARS-CoV-2 VLPs production and chromatographic purification.

show abstract

Section: Introductionmentioning

confidence: 99%